Protara Therapeutics, Inc. Common Stock

TARANASDAQ • USD
2.47 USD
↗ 0.12 (5.11%)AT CLOSE (03:59 PM EDT)
2.54
↗ 0.07 (3.00%)
POST MARKET (AS OF 05:35 PM EDT)
Post Market
AS OF 05:35 PM EDT
2.54
↗ 0.07 (3.00%)
🟢Market: OPEN

Protara Therapeutics, Inc. Common Stock (TARA) is currently trading at $2.54. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Oct 27, 2026.

Open?$2.33
High?$2.48
Low?$2.31
Prev. Close?$2.35
Volume?1.8M
Avg. Volume?1.6M
VWAP?$2.42
Rel. Volume?1.18x
Bid / Ask
Bid?$2.12 × 100
Ask?$2.93 × 100
Spread?$0.81
Midpoint?$2.53
Valuation & Ratios
Market Cap?138.9M
Shares Out?59.1M
Float?54.8M
Float %?92.7%
P/E Ratio?N/A
P/B Ratio?0.86
EPS?-$1.18
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
Employees
51
Market Cap
138.9M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2020-01-10
Address
345 PARK AVENUE SOUTH
NEW YORK, NY 10010
Phone: 646-844-0337
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
49
Momentum?
50
Short Sent.?
55
Piotroski F-Score?0/9Weak
Altman Z-Score?2.39Grey
Confidence?53%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?11.13%High
Short Interest?6.1M
Days to Cover?4.3
Free Float54.8M
Avg Daily Volume1.4M
Settlement Date2026-10-15
Financial Health
Current Ratio?10.97Strong
Quick Ratio?10.97Strong
Cash Ratio?1.28Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.86CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.6CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-43.4%WEAK▾
ROA?
S&P
3
-39.8%WEAK▾
Cash Flow & Enterprise
FCF?$-66494000
Enterprise Value?$121.8M
Fundamentals ratios updated end of day